| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | -0.0096 | 0.9 |
| mRNA | KU-60019 | CTRPv2 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | SJ-172550 | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | -0.022 | 0.9 |
| mRNA | BRD-K24690302 | CTRPv2 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | -0.018 | 0.9 |
| mRNA | Pazopanib | FIMM | pan-cancer | AAC | 0.022 | 0.9 |
| mRNA | BRD9647 | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | Cyclopamine | GDSC1000 | pan-cancer | AAC | 0.0061 | 0.9 |